Altimmune
ALT
97 hedge funds and large institutions have $337M invested in Altimmune in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 36 increasing their positions, 21 reducing their positions, and 16 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 21
56% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 16
46% more capital invested
Capital invested by funds: $231M → $337M (+$106M)
21% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $9.04M
9% more funds holding
Funds holding: 89 → 97 (+8)
2.23% more ownership
Funds ownership: 61.91% → 64.14% (+2.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$47.6M |
| 2 |
CCM
CAAS Capital Management
New York
|
+$17.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$14.1M |
| 4 |
AC
Armistice Capital
New York
|
+$8.67M |
| 5 |
Millennium Management
New York
|
+$5.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$21.2M |
| 2 |
VA
VR Adviser
New York
|
-$16.2M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$4.73M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$4.52M |
| 5 |
EP
Eversept Partners
New York
|
-$4.29M |
ALT Hedge Fund Activity: Q1 2021 in Review
97 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2021, worth a combined $337M — up 46% from $231M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ALT positions and 16 closed out — a net gain of 9 holders — while 36 added to existing stakes and 21 trimmed.
The largest buyer was State Street, opening a new position worth an estimated $47.6M. The largest seller was UBS Group, cutting an estimated $21.2M.
- 97 institutional investors held Altimmune (ALT) as of Q1 2021, up from 89 in Q4 2020.
- Funds reported $337M of Altimmune stock for Q1 2021, up 46% quarter-over-quarter.
- 25 funds opened new Altimmune positions in Q1 2021 and 16 closed out, a net change of +9 holders.
- The largest Altimmune buyer in Q1 2021 was State Street, an estimated $47.6M added.
- The largest Altimmune seller in Q1 2021 was UBS Group, an estimated $21.2M sold.
Based on aggregated 13F filings for Q1 2021.